S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

Allarity Therapeutics Stock Forecast, Price & News

+0.03 (+1.70%)
(As of 06/24/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
59,329 shs
Average Volume
266,463 shs
Market Capitalization
$16.61 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive ALLR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allarity Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALLR Stock Forecast (MarketRank)

Overall MarketRank

1.83 out of 5 stars

Medical Sector

757th out of 1,411 stocks

Pharmaceutical Preparations Industry

368th out of 672 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
Allarity Therapeutics logo

About Allarity Therapeutics (NASDAQ:ALLR)

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

ALLR Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
1 Analysts


Pretax Margin


Sales & Book Value

Annual Sales


Free Float
Market Cap
$16.61 million
Not Optionable

Allarity Therapeutics Frequently Asked Questions

Should I buy or sell Allarity Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allarity Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Allarity Therapeutics stock.
View analyst ratings for Allarity Therapeutics
or view top-rated stocks.

What is Allarity Therapeutics' stock price forecast for 2022?

1 Wall Street research analysts have issued twelve-month price targets for Allarity Therapeutics' shares. Their ALLR stock forecasts range from $8.00 to $8.00. On average, they predict Allarity Therapeutics' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 346.9% from the stock's current price.
View analysts' price targets for Allarity Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Allarity Therapeutics' stock performed in 2022?

Allarity Therapeutics' stock was trading at $10.75 at the start of the year. Since then, ALLR shares have decreased by 83.3% and is now trading at $1.79.
View the best growth stocks for 2022 here

Who are Allarity Therapeutics' key executives?

Allarity Therapeutics' management team includes the following people:
  • Mr. Stefano R. Carchedi, CEO, Pres & Director (Age 60, Pay $669.58k)
  • Mr. Jens Erik Knudsen CPA, M.B.A., Chief Financial Officer (Age 53, Pay $333.62k)
  • Mr. James G. Cullem J.D., Sr. VP of Corp. Devel. (Age 52, Pay $356.85k)
  • Dr. Marie Foegh DrSc, M.D., Chief Medical Officer (Age 78, Pay $424.08k)
  • Mr. Peter Buhl Jensen Adj Professor, M.D., M.D., Ph.D., Ph.D., Co-Founder (Age 67)
  • Dr. Steen Meier Knudsen Ph.D., Founder & Chief Scientific Officer (Age 61)
  • Ms. Ulla Hald Buhl, Founder, COO, Chief IR & Communications (Age 58)
  • Mr. Thomas H. Jensen, Founder & Sr. VP of Information Technologies (Age 44)
  • Mr. Claus Frisenberg Pedersen, Chief Commercial Officer (Age 50)
  • Ms. Annie Rasmussen, Chief of Clinical Operations (Age 65)

What is Allarity Therapeutics' stock symbol?

Allarity Therapeutics trades on the NASDAQ under the ticker symbol "ALLR."

Who are Allarity Therapeutics' major shareholders?

Allarity Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (0.00%).

Which major investors are buying Allarity Therapeutics stock?

ALLR stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.

How do I buy shares of Allarity Therapeutics?

Shares of ALLR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Allarity Therapeutics' stock price today?

One share of ALLR stock can currently be purchased for approximately $1.79.

How much money does Allarity Therapeutics make?

Allarity Therapeutics (NASDAQ:ALLR) has a market capitalization of $16.61 million.

How many employees does Allarity Therapeutics have?

Allarity Therapeutics employs 14 workers across the globe.

How can I contact Allarity Therapeutics?

The official website for Allarity Therapeutics is www.allarity.com. The company can be reached via phone at 401-426-4664.

This page (NASDAQ:ALLR) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.